# Deferoxamine for Sickle Cell Chronic Leg Ulcer Treatment

> **NCT04058197** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **TauTona Group**

## Conditions studied

- Chronic Cutaneous Ulcer
- Sickle Cell Disease

## Interventions

- **DRUG:** Deferoxamine Product
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04058197
- **Lead sponsor:** TauTona Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-07-21
- **Primary completion:** 2021-10-06
- **Final completion:** 2021-10-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of enrollment
- **Last updated:** 2021-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04058197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04058197, "Deferoxamine for Sickle Cell Chronic Leg Ulcer Treatment". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04058197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*